LDL Particle Number Measured Using NMR Clinical Analyzer
|
By LabMedica International staff writers Posted on 25 Aug 2014 |
|
Image: The Vantera Clinical Analyzer offers the technology that has the ability to directly enumerate low-density lipoprotein (LDL) particle numbers (Photo courtesy of LipoScience).
Fully-automated high-throughput nuclear magnetic resonance (NMR) spectroscopy has been developed to enable measurements in a clinical laboratory setting.
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Automatic CLIA Analyzer
Shine i6000
Latest Clinical Chem. News
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
Channels
Molecular Diagnostics
view channel
New Gene Signature Reveals Underdiagnosed Lung Cancer Subtype
Combined small-cell lung cancer (cSCLC) is a rare lung malignancy in which tumors display both small-cell and non-small-cell features. These mixed tumors are commonly managed as standard small-cell disease... Read more
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Hematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Immunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Microbiology
view channel
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
Pathology
view channel
AI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read more
